Impact of SARS-CoV-2 Treatment on Development of Sensorineural Hearing Loss
Impact of SARS-CoV-2 treatment on SNHL
Keywords:
SARS-CoV-2, COVID-19, toxicity, sensorineural hearing loss, antimalarials,, anti-viralsAbstract
Ototoxicity had been a known viral manifestation. This raised the possibility for the current pandemic
caused by the novel coronavirus to induce temporary or permanent auditory manifestations. The struggle to search
for therapeutic options to counter the pandemic is still underway. Meanwhile, the management had relied on using antimalarials and antivirals; which themselves have proven ototoxic repercussions. Interestingly this brings to a point of further debate whether the auditory dysfunction is induced by the virus alone or by the drugs that are used to pacify the pathology of the viral exhibition or both. This article will channel this current implication of the hearing loss debate focusing on the mainstay regimen for SARS-CoV-2 management. A bibliographic search was performed to review current literature in scientific databases PubMed, Research Gate, and Google Scholar. Published articles encompassed within our inclusion criteria were reviewed thoroughly to draw possible outcomes. Reported SARSCoV-2 manifestations are sensorineural hearing loss with disturbed vestibulo-auditory symptoms. Reviewed research data suggested aggravation in ototoxicity induced by these medications. This upsurges the controversies surrounding the safety and efficacy of the medications currently in active use for managing SARS-CoV-2 infection. Further therapeutic strategies need to be researched for equipping the arsenal to effectively treating SARS-CoV-2 and its
complications.
References
J. Saniasiaya, “Hearing Loss in SARS-CoV-2: What Do We Know?,” Ear, nose, & throat journal 100: 152S-154S, (2021).
B. E. Cohen, A. Durstenfeld, and P. C. Roehm, “Viral causes of hearing loss: a review for hearing health professionals,” Trends in hearing 18: 2331216514541361 (2014).
X. Chen, Y.-Y. Fu, and T.-Y. Zhang, “Role of viral infection in sudden hearing loss,” The Journal of international medical research 47: 2865-2872 (2019).
J. Zheng, “SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat,” International journal of biological sciences 16: 1678-1685 (2020).
I. Astuti, and Ysrafil, “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response,” Diabetes & metabolic syndrome 14: 407-412 (2020).
S. Villapol, “Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome,” Translational research : The journal of laboratory and clinical medicine 226: 57-69 (2020).
X. Chen, “Potential neuroinvasive and neurotrophic properties of SARS-CoV-2 in pediatric patients: comparison of SARS-CoV-2 with non-segmented RNA viruses,” Journal of NeuroVirology 26: 929-940 (2020).
P. Horby, M. Mafham, L. Linsell, J. L. Bell, N. Staplin, J. R. Emberson, M. Wiselka, A. Ustianowski, E. Elmahi, B. Prudon, A. Whitehouse, T. Felton, J. Williams, J. Faccenda, J. Underwood, J. K. Baillie, L. Chappell, S. N. Faust, T. Jaki, K. Jeffery, W. S. Lim, A. Montgomery, K. Rowan, J. Tarning, J. A. Watson, N. J. White, E. Juszczak, R. Haynes, and M. J. Landray, “Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial,” medRxiv: 2020.07.15.20151852 (2020).
P. Horby, M. Mafham, L. Linsell, J. L. Bell, N. Staplin, J. R. Emberson, M. Wiselka, A. Ustianowski, E. Elmahi, and B. Prudon, “Effect of
Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial,” MedRxiv, (2020).
W. Tang, Z. Cao, M. Han, Z. Wang, J. Chen, W. Sun, Y. Wu, W. Xiao, S. Liu, and E. Chen, “Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial,” bmj 369 (2020).
Z. Jie, H. He, H. Xi, and Z. Zhi, “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia,” Zhonghua Jie He He Hu Xi Za Zhi 43: 185-188 (2020).
C. Lanvers-Kaminsky, A. A. Zehnhoff-Dinnesen, R. Parfitt, and G. Ciarimboli, “Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies,” Clin Pharmacol Ther 101: 491-500 (2017).
M. A. Chary, A. F. Barbuto, S. Izadmehr, B. D. Hayes, and M. M. Burns, “COVID-19: therapeutics and their toxicities,” Journal of Medical Toxicology 16: 284-294 (2020).
C. Lanvers‐Kaminsky, A. a. Zehnhoff‐Dinnesen, R. Parfitt, and G. Ciarimboli, “Drug‐induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies,” Clinical pharmacology & therapeutics 101: 491-500 (2017).
C. Little, and M. K. Cosetti, “A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity,” Laryngoscope (2021).
M. Abbasi, Z. Yazdi, A. M. Kazemifar, and Z. Z. Bakhsh, “Hearing loss in patients with systemic lupus erythematosus,” Global Journal of Health Science 5: 102 (2013).
B. Mégarbane, and J.-M. Scherrmann, “Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?,” Journal of clinical pharmacology 60: 808-814 (2020).
F. R. Lin, K. Yaffe, J. Xia, Q.-L. Xue, T. B. Harris, E. Purchase-Helzner, S. Satterfield, H. N. Ayonayon, L. Ferrucci, and E. M. Simonsick, “Hearing loss and Lim, A. Montgomery, K. Rowan, J. Tarning, J. A. Watson, N. J. White, E. Juszczak, R. Haynes, and M. J. Landray, “Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled
trial,” medRxiv: 2020.07.15.20151852 (2020).
P. Horby, M. Mafham, L. Linsell, J. L. Bell, N. Staplin, J. R. Emberson, M. Wiselka, A. Ustianowski, E. Elmahi, and B. Prudon, “Effect of
Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial,” MedRxiv, (2020).
W. Tang, Z. Cao, M. Han, Z. Wang, J. Chen, W. Sun, Y. Wu, W. Xiao, S. Liu, and E. Chen, “Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial,” bmj 369 (2020).
Z. Jie, H. He, H. Xi, and Z. Zhi, “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia,” Zhonghua Jie He He Hu Xi Za Zhi 43: 185-188 (2020).
C. Lanvers-Kaminsky, A. A. Zehnhoff-Dinnesen, R. Parfitt, and G. Ciarimboli, “Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies,” Clin Pharmacol Ther 101: 491-500 (2017).
M. A. Chary, A. F. Barbuto, S. Izadmehr, B. D. Hayes, and M. M. Burns, “COVID-19: therapeutics and their toxicities,” Journal of Medical Toxicology 16: 284-294 (2020).
C. Lanvers‐Kaminsky, A. a. Zehnhoff‐Dinnesen, R. Parfitt, and G. Ciarimboli, “Drug‐induced ototoxicity: mechanisms, pharmacogenetics, and protective strategies,” Clinical pharmacology & therapeutics 101: 491-500 (2017).
C. Little, and M. K. Cosetti, “A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity,” Laryngoscope (2021).
M. Abbasi, Z. Yazdi, A. M. Kazemifar, and Z. Z. Bakhsh, “Hearing loss in patients with systemic lupus erythematosus,” Global Journal of Health Science 5: 102 (2013).
B. Mégarbane, and J.-M. Scherrmann, “Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?,” Journal of clinical pharmacology 60: 808-814 (2020).
F. R. Lin, K. Yaffe, J. Xia, Q.-L. Xue, T. B. Harris, E. Purchase-Helzner, S. Satterfield, H. N. Ayonayon, L. Ferrucci, and E. M. Simonsick, “Hearing loss and cognitive decline in older adults,” JAMA internal medicine 173: 293-29 (2013).
K.-M. Han, Y.-H. Ko, C. Shin, J.-H. Lee, J. Choi, D.-Y. Kwon, H.-K. Yoon, C. Han, and Y.-K. Kim, “Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample,” Journal of Psychiatric Research 98: 124-132 (2018).
K. J. Trevis, N. M. McLachlan, and S. J. Wilson, “A systematic review and meta-analysis of psychological functioning in chronic tinnitus,”
Clinical psychology review, 60: 62-86 (2018).
J. C. Alyono, “Vertigo and dizziness: understanding and managing fall risk,” Otolaryngologic Clinics of North America 51: 725-740 (2018).
S. Abd-Elsalam, E. S. Esmail, M. Khalaf, E. F. Abdo, M. A. Medhat, M. S. Abd El Ghafar, O. A. Ahmed, S. Soliman, G. N. Serangawy, and M.
Alboraie, “Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study,” The American journal of tropical medicine and hygiene 103: 1635-1639 (2020).
A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, and S. Einav, “A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19,” J Crit Care, 57: 279-283 (2020).
Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han, D. Yan, R. Zhuang, B. Hu, and Z. Zhang, “Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial,” medRxiv 2020.03.22.20040758 (2020).
M. R. Mehra, S. S. Desai, F. Ruschitzka, and A. N. Patel, “RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,” Lancet (London, England) S0140-6736(20)31180-6 (2020).
Ü. Türsen, B. Türsen, and T. Lotti, “Cutaneous sıde-effects of the potential COVID-19 drugs,” Dermatologic therapy 33: e13476-e13476 (2020).
C. A. Devaux, J. M. Rolain, P. Colson, and D. Raoult, “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,” Int J Antimicrob Agents 55: 105938 (2020).
P. Prayuenyong, A. V. Kasbekar, and D. M. Baguley, “Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review,” Frontiers in public health 8: 252-252 (2020).
D. K. Mukherjee, “Chloroquine ototoxicity--a reversible phenomenon?,” J Laryngol Otol 93: 809-15 (1979).
P. Prayuenyong, A. V. Kasbekar, and D. M. Baguley, “Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review,” Frontiers in Public Health 8: 252 (2020).
P. Bernard, “Alterations of auditory evoked potentials during the course of chloroquine treatment,” Acta Otolaryngol 99: 387-92 (1985).
U. Hadi, N. Nuwayhid, and A. S. Hasbini, “Chloroquine ototoxicity: an idiosyncratic phenomenon,” Otolaryngol Head Neck Surg 114:
-3 (1996).
H. Khalili, F. Dastan, and S. A. Dehghan Manshadi, “A case report of hearing loss post use DARU Journal of Pharmaceutical Sciences 22: 20 (2014).
U. Seçkin, K. Ozoran, A. Ikinciogullari, P. Borman, and E. E. Bostan, “Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis,” Rheumatol Int 19: 203-4 (2000).
M. R. N. Fernandes, D. B. R. Soares, C. I. Thien, and S. Carneiro, “Hydroxychloroquine ototoxicity in a patient with systemic lupus erythematosus,” An Bras Dermatol 93: 469-470 (2018).
P. B. Johansen, and J. T. Gran, “Ototoxicity due to hydroxychloroquine: report of two cases,” Clin Exp Rheumatol 16: 472-4 (1998).
J. Gao, Z. Tian, and X. Yang, “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies,” Biosci Trends 14: 72-73 (2020).
X. Yao, F. Ye, M. Zhang, C. Cui, B. Huang, P. Niu, X. Liu, L. Zhao, E. Dong, C. Song, S. Zhan, R. Lu, H. Li, W. Tan, and D. Liu, “In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),” Clin Infect Dis 71: 732-739 (2020).
P. Gautret, J. C. Lagier, P. Parola, V. T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. E. Vieira, H. Tissot Dupont, S. Honoré, P. Colson, E. Chabrière, B. La Scola, J. M. Rolain, P. Brouqui, and D. Raoult, “Hydroxychloroquine and azithromycin as a
treatment of COVID-19: results of an open-label non-randomized clinical trial,” Int J Antimicrob Agents 56: 105949 (2020).
C. A. C. Garcia, E. B. A. Sanchez, D. H. Huerta, and J. Gomez-Arnau, “Covid-19 treatment-induced neuropsychiatric adverse effects,” Gen Hosp Psychiatry 67: 163-164 (2020).
B. Williams, “Ototoxicity may be associated with protease inhibitor therapy,” Clin Infect Dis 33: 2100-2 (2001).
S. M. Makau, B. A. Ongulo, and P. Mugwe, “The pattern of hearing disorders in HIV positive patients on anti-retrovirals at Kenyatta National Hospital,” East Afr Med J 87: 425-9 (2010).
P. W. Horby, M. Mafham, J. L. Bell, L. Linsell, N. Staplin, J. Emberson, A. Palfreeman, J. Raw, E. Elmahi, B. Prudon, C. Green, S. Carley, D.
Chadwick, M. Davies, M. P. Wise, J. K. Baillie, L. C. Chappell, S. N. Faust, T. Jaki, K. Jefferey, W. S. Lim, A. Montgomery, K. Rowan, E. Juszczak, R. Haynes, and M. J. Landray, “Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, openlabel, platform trial,” The Lancet 396: 1345-1352 (2020).
M. S. Abers, W. X. Shandera, and J. S. Kass, “Neurological and psychiatric adverse effects of antiretroviral drugs,” CNS Drugs 28: 131-45 (2014).
I. F.-N. Hung, K.-C. Lung, E. Y.-K. Tso, R. Liu, T. W.-H. Chung, M.-Y. Chu, Y.-Y. Ng, J. Lo, J. Chan, and A. R. Tam, “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial,” The Lancet 395: 1695-1704 (2020).
E. Formann, R. Stauber, D.-M. Denk, W. Jessner, G. Zollner, P. Munda-Steindl, A. Gangl, and P. Ferenci,“Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin,” LWW, (2004).
S. Jain, V. Midha, and A. Sood, “Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy,” Indian Journal of Gastroenterology 30: 239-240 (2011).
V. Le, T. Bader, and J. Fazili, “A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone,” Nature Clinical Practice Gastroenterology & Hepatology 6: 57-60 (2009).
A. Piekarska, M. Jozefowicz-Korczynska, K. Wojcik, and E. Berkan, “Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon andribavirin: Hipoacusia súbita en un paciente con síndrome de Turner y hepatitis crónica C tratado con interferón pegilado y ribavirina,” International journal of audiology 46: 345-350 (2007).
A. J. Szczepek, “Ototoxicity: Old and new foes,” Advances in Clinical Audiology (2017).
L. Caly, J. D. Druce, M. G. Catton, D. A. Jans, and K. M. Wagstaff, “The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,” Antiviral research 178: 104787 (2020).
J. Echevarria, J.-A. Perez-Molina, F. Samalvides, M.-N. Plana, E. Gotuzzo, A. C. White Jr, A. Terashima, and C. Henriquez-Camacho, “Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection” (2016).
V. Bussaratid, S. Krudsood, U. Silachamroon, and S. Looareesuwan, “Tolerability of ivermectin in gnathostomiasis,” Southeast Asian Journal of Tropical Medicine and Public Health 36: 644 (2005).
C. H. Norris, “Drugs affecting the inner ear. A review of their clinical efficacy, mechanisms of action, toxicity, and place in therapy,” Drugs 36: 754-72 (1988).
M. D. Morrison, and B. W. Blakley, “The effects of indomethacin on inner ear fluids and morphology,” J Otolaryngol 7: 149-57 (1978).
D. H. Tran, R. Sugamata, T. Hirose, S. Suzuki, Y. Noguchi, A. Sugawara, F. Ito, T. Yamamoto, S. Kawachi, and K. S. Akagawa, “Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process,” The Journal of antibiotics 72: 759-768 (2019).
J. F. Bermejo-Martin, D. J. Kelvin, J. M. Eiros, J. Castrodeza, and R. O. De Lejarazu, “Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains,” The Journal of Infection in Developing Countries 3: 159-161 (2009).
P. Gautret, J.-C. Lagier, P. Parola, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V. E. Vieira, and H. T. Dupont, “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial,” International journal of antimicrobial agents 56: 105949 (2020).
N. Naksuk, S. Lazar, and T. Peeraphatdit, “Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol,” European Heart Journal: Acute Cardiovascular Care 9: 215-221 (2020).
Q. Zhou, V. Chen, C. P. Shannon, X.-S. Wei, X. Xiang, X. Wang, Z.-H. Wang, S. J. Tebbutt, T. R. Kollmann, and E. N. Fish, “Interferon-α2b Treatment for COVID-19,” Frontiers in immunology 11: 1061 (2020).
F. Dastan, S. A. Nadji, A. Saffaei, M. Marjani, A. Moniri, H. Jamaati, S. M. Hashemian, P. Baghaei, A. Abedini, and M. Varahram, “Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial,” International
immunopharmacology 85: 106688 (2020).
Y. Kanda, K. Shigeno, H. Matsuo, M. Yano, N. Yamada, and H. Kumagami, “Interferon-lnduced Sudden Hearing Loss: Original Paper,” Audiology 34: 98-102 (1995).
M. R. Sharifian, S. Kamandi, H. R. Sima, M. A. Zaringhalam, and M. Bakhshaee, “INF-α and ototoxicity,” BioMed research international 2013 (2013).
M. U. Akyol, S. Sarac, G. Akyol, A. Atac, A. Poyraz, E. Belgin, and E. Turan, “Investigation of the ototoxic effects of interferon α2A on the mouse cochlea,” Otolaryngology—Head and Neck Surgery 124: 107-110 (2001).
G. Cianfrone, D. Pentangelo, F. Cianfrone, F. Mazzei, R. Turchetta, M. Orlando, and G. Altissimi, “Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide,” Eur Rev Med Pharmacol Sci 15: 601-36 (2011).
C. Ronco, T. Reis, and F. Husain-Syed, “Management of acute kidney injury in patients with COVID-19,” The Lancet Respiratory Medicine (2020).
A. Howarth, and G. Shone, “Ageing and the auditory system,” Postgraduate medical journal 82: 166-171, (2006).
R. L. Hybels, “Drug toxicity of the inner ear,” Medical Clinics of North America 63: 309-319 (1979).
P. Bernard, “Alterations of auditory evoked potentials during the course of chloroquine treatment,” Acta oto-laryngologica 99: 387-392 (1985).
V. Subramaniam, and R. Vaswani, “Assessment of short term chloroquine-induced ototoxicity in malaria patients,” Global J Med Res 15: 14-17 (2015).
G. Dwivedi, and Y. Mehra, “Ototoxicity of chloroquine phosphate: a case report,” The Journal of Laryngology & Otology 92: 701-703 (1978).
R. Bortoli, and M. Santiago, “Chloroquine ototoxicity,” Clinical rheumatology 26: 1809-1810 (2007).
U. Hadi, N. Nuwayhid, and A. S. Hasbini, “Chloroquine ototoxicity: an idiosyncratic phenomenon,” Otolaryngology—Head and Neck
Surgery 114: 491-493 (1996).
P. Thein, G. M. Kalinec, C. Park, and F. Kalinec, “In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity,” Hearing research 310: 27-35 (2014).
B. Williams, “Ototoxicity may be associated with protease inhibitor therapy,” Clinical infectious diseases 33: 2100-2101 (2001).
M. C. J. Mendes-Corrêa, R. S. M. Bittar, N. Salmito, and J. Oiticica, “Pegylated interferon/ribavirinassociated sudden hearing loss in a patient with chronic hepatitis C in Brazil,” The Brazilian Journal of Infectious Diseases 15: 87-89 (2011).
M. Bisht, and S. Bist, “Ototoxicity: the hidden menace,” Indian Journal of Otolaryngology and Head & Neck Surgery 63: 255-259 (2011).
J. A. Brien, “Ototoxicity associated with salicylates. A brief review,” Drug Saf 9: 143-8 (1993).
C. H. Norris, “Drugs affecting the inner ear,” Drugs 36: 754-772 (1988).
M. Morrison, and B. Blakley, “The effects of indomethacin on inner ear fluids and morphology,” The Journal of otolaryngology 7: 149-157 (1978).
A. L. Tseng, L. Dolovich, and I. E. Salit, “Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus,”
Clinical infectious diseases 24: 76-77 (1997).
Downloads
Published
How to Cite
Issue
Section
License
Creative Commons Attribution (CC BY). Allows users to: copy the article and distribute; abstracts, create extracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: includes a link to the license; indicates if changes were made; gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
